SCHEMBL517566

SCHEMBL517566

COc1cc(N2CCC(N3CCN(C(C)C)CC3)CC2)ccc1[N+](=O)[O-]

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.61
LMNA P02545 2/20 0.61
MAPT P10636 7/20 0.59
SIRT6 Q8N6T7 1/20 0.59
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
PLK1 P53350 4/20 0.44
HTR6 P50406 1/20 0.43
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
HPGD P15428 1/20 0.40
VCP P55072 1/20 0.40
BMPR1B O00238 1/20 0.40
PLK4 O00444 1/20 0.40
GAK O14976 1/20 0.40
ERN1 O75460 1/20 0.40
STK10 O94804 1/20 0.40
ABL1 P00519 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL309624 0.89 SIRT6 (0.74) ALDH1A1LMNAMAPTSIRT6KMT2A
SCHEMBL375616 0.88 SIRT6 (0.77) ALDH1A1LMNAMAPTSIRT6MEN1
SCHEMBL520231 0.88 ALDH1A1 (0.76) ALDH1A1LMNAMAPTSIRT6MEN1
SCHEMBL311491 0.86 ALDH1A1 (0.74) ALDH1A1LMNAMAPTSIRT6MEN1
SCHEMBL311063 0.85 ALDH1A1 (0.65) ALDH1A1LMNAMAPTSIRT6MEN1
SCHEMBL2062143 0.85 SIRT6 (0.77) ALDH1A1LMNAMAPTSIRT6MEN1
SCHEMBL3722026 0.85 ALDH1A1 (0.65) ALDH1A1LMNAMAPTSIRT6MEN1
SCHEMBL26043874 0.85 ALDH1A1 (0.72) ALDH1A1LMNAMAPTSIRT6MEN1
SCHEMBL23534178 0.85 SIRT6 (0.65) ALDH1A1LMNAMAPTSIRT6MEN1
SCHEMBL29709935 0.85 SIRT6 (0.65) ALDH1A1LMNAMAPTSIRT6MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2601186-A2 4-(1H-INDOL-3-YL)-PYRIMIDINES AS ALK INHIBITORS AstraZeneca AB (SE) 2013-06-12 EP disclosed
US-8461170-B2 Chemical compounds ASTRAZENECA AB (SE) 2013-06-11 US disclosed
US-8461170-B2 Chemical compounds ASTRAZENECA AB (SE) 2013-06-11 US disclosed
US-8461170-B2 Chemical compounds ASTRAZENECA AB (SE) 2013-06-11 US disclosed
WO-2012017239-A2 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2012-02-09 WO disclosed
WO-2012017239-A2 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2012-02-09 WO disclosed
US-20120028924-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2012-02-02 US disclosed
US-20120028924-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2012-02-02 US disclosed
US-20120028924-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2012-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028924-A1 CHEMICAL COMPOUNDS ALK, BRAF, ABL1 ALDH1A1 214/4885LMNA 1889/4885MAPT 2815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.